A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)

Giant cell arteritis (GCA)

Sustained remission at Week 52 as per definition of sustained remission in the protocol.

Time to clinical failure as measured in days through Week 52 per definition of clinical failure in the protocol., Cumulative GC dose through Week 52, Sustained remission at Week 52, Time to clinical failure as measured in days through Week 52, Change in SF-36 score (PCS) at Week 52, Change in Glucocorticoid Toxicity Index (GTI) as measured by the Aggregate Improvement Score (AIS) at Week 52, Change in FACIT-Fatigue score at Week 52, Safety and tolerability demonstrated by assessing: Adverse events (AEs) and serious adverse events (SAEs) (incidence, severity, and relationship to study drug) Changes in laboratory measures and vital signs

No related papers found yet.

Austria, Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Norway, Poland, Portugal, Spain, Sweden